BioNTech Showcases AI Progress at AI Day

TL;DR

BioNTech is going all-in on AI for drug discovery, presenting its latest AI tech via InstaDeep.

AI Summary

On October 1, 2024, BioNTech SE announced its participation in the AI Day presentation, highlighting its advancements in artificial intelligence through its subsidiary InstaDeep Ltd. The company is leveraging AI to drive innovation across its drug discovery and development processes.

Why It Matters

BioNTech's focus on AI integration signals a commitment to accelerating drug development timelines and potentially discovering novel therapies, which could impact future healthcare solutions.

Risk Assessment

Risk Level: low — This filing is an informational update about a presentation and does not contain material financial changes or new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• InstaDeep Ltd. (company) — AI subsidiary
• October 1, 2024 (date) — Date of announcement

FAQ

From the Filing

0001776985-24-000083.txt : 20241001 0001776985-24-000083.hdr.sgml : 20241001 20241001081203 ACCESSION NUMBER: 0001776985-24-000083 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 139 CONFORMED PERIOD OF REPORT: 20241001 FILED AS OF DATE: 20241001 DATE AS OF CHANGE: 20241001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241341384 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kaidaypresentationpr.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On October 1, 2024, BioNTech SE (the “Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd., is presenting an overview of its AI approach during an edition of the Company’s Innovation Series, AI Day. The press release and presentation are attached as Exhibits 99.1 and 99.2, respectively. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: October 1, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day 99.2 Presentation EX-99.1 2 ex9920241001_innovationser.htm EX-99.1 Document Exhibit 99.1 BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day • Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline • Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale • Unveils novel AI Bayesian Flow Network (“BFN”) models for protein sequence generation • Highlights progress in deploying AI across BioNTech’s immunotherapy pipeline, including in immunohistochemistry, DNA/RNA sequencing, proteomics, protein design, and lab functional validation LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd. (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company’s Innovation Series, AI Day. “At BioNTech, we are at the forefront of integrating advanced AI to revolutionize individualized medicine. With our in-house AI spe